Recent advances in the discovery of small-molecule ATP competitive mTOR inhibitors: a patent review (Q37876907)

24 August 2017

1 reference

title

Recent advances in the discovery of small-molecule ATP competitive mTOR inhibitors: a patent review (English)

1 reference

24 August 2017

Arie Zask

1

1 reference

24 August 2017

Jeroen C Verheijen

series ordinal

2

1 reference

24 August 2017

David J Richard

series ordinal

3

1 reference

24 August 2017

language of work or name

English

0 references

publication date

19 May 2011

1 reference

Expert Opinion on Therapeutic Patents

24 August 2017

1 reference

24 August 2017

21

1 reference

24 August 2017

7

1 reference

24 August 2017

1109-1127

1 reference

The mammalian target of rapamycin signaling pathway: twists and turns in the road to cancer therapy

24 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.584871

Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.584871

mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.584871

AZD8055 is a potent, selective, and orally bioavailable ATP-competitive mammalian target of rapamycin kinase inhibitor with in vitro and in vivo antitumor activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.584871

Discovery of GSK2126458, a Highly Potent Inhibitor of PI3K and the Mammalian Target of Rapamycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.584871

Allosteric and ATP-competitive kinase inhibitors of mTOR for cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.584871

Morpholine derivatives greatly enhance the selectivity of mammalian target of rapamycin (mTOR) inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.584871

Structural Determinants of Phosphoinositide 3-Kinase Inhibition by Wortmannin, LY294002, Quercetin, Myricetin, and Staurosporine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.584871

Synthesis and biological evaluation of pyrido[3',2':4,5]furo[3,2-d]pyrimidine derivatives as novel PI3 kinase p110alpha inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.584871

Discovery of 4-morpholino-6-aryl-1H-pyrazolo[3,4-d]pyrimidines as highly potent and selective ATP-competitive inhibitors of the mammalian target of rapamycin (mTOR): optimization of the 6-aryl substituent.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.584871

ATP-competitive inhibitors of the mammalian target of rapamycin: design and synthesis of highly potent and selective pyrazolopyrimidines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.584871

Bis(morpholino-1,3,5-triazine) derivatives: potent adenosine 5'-triphosphate competitive phosphatidylinositol-3-kinase/mammalian target of rapamycin inhibitors: discovery of compound 26 (PKI-587), a highly efficacious dual inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.584871

Discovery of 2-ureidophenyltriazines bearing bridged morpholines as potent and selective ATP-competitive mTOR inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.584871

2-Arylureidophenyl-4-(3-oxa-8-azabicyclo[3.2.1]octan-8-yl)triazines as highly potent and selective ATP competitive mTOR inhibitors: optimization of human microsomal stability

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.584871

Triazines incorporating (R)-3-methylmorpholine are potent inhibitors of the mammalian target of rapamycin (mTOR) with selectivity over PI3Kalpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.584871

4-methylpteridinones as orally active and selective PI3K/mTOR dual inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.584871

Discovery of 1-(4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo[h][1,6]naphthyridin-2(1H)-one as a highly potent, selective mammalian target of rapamycin (mTOR) inhibitor for the treatment of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.584871

10.1517/13543776.2011.584871

21 January 2018

Identifiers

DOI

1 reference

24 August 2017

1 reference